Santhera Enters into Agreement to Acquire Option for Exclusive Sub-License of Vamorolone
PPMD has learned that Santhera Pharmaceuticals and Idorsia Ltd have entered into an agreement under which Santhera will acquire the option to exclusively in-license vamorolone, currently being developed by Reveragen. Idorsia currently holds the license…Learn More